Grant of Share Options

RNS Number : 5186M

Destiny Pharma PLC

21 January 2021

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Brighton, United Kingdom - 21st January 2021 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over a total of 180,436 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following Directors and PDMRs in respect of bonuses due for the financial year ended 31 December 2020:

Name	Position	Total number of Options granted under award	Total Options held after the grant
Neil Clark	Chief Executive Officer	53,053	1,156,745
Shaun Claydon	Chief Financial Officer	39,230	700,768
William Love	Chief Scientific Officer	45,095	1,176,000
Jesus Gonzalez	Chief Medical Officer	43,058	492,242

The Options have been granted with a nominal exercise price and will vest on 21 January 2023.

Enquiries:

Destiny Pharma plc	[phone]
Neil Clark (Chief Executive Officer) Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker	[phone]
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) Alice Lane (ECM)
WG Partners LLP - Joint Broker	[phone]
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communications	[phone]
Mary Clark / Shabnam Bashir / Manel Mateus

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share  53,053 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	21 January 2021
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 39,230 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	21 January 2021
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bill Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 45,095 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	21 January 2021
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jesus Gonzalez
2.	Reason for the Notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 43,058 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	21 January 2021
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

DSHUAONRARUAUAR